Celldex Therapeutics
CLDX
160 hedge funds and large institutions have $2.33B invested in Celldex Therapeutics in 2021 Q3 according to their latest regulatory filings, with 44 funds opening new positions, 52 increasing their positions, 46 reducing their positions, and 14 closing their positions.
214% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 14
120% more funds holding in top 10
Funds holding in top 10: 5 → 11 (+6)
95% more capital invested
Capital invested by funds: $1.19B → $2.33B (+$1.14B)
23% more call options, than puts
Call options by funds: $85.9M | Put options by funds: $69.9M
22% more funds holding
Funds holding: 131 → 160 (+29)
13% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 46
3.44% more ownership
Funds ownership: 89.06% → 92.5% (+3.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$246M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$75.1M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
+$35.8M |
| 4 |
CAC
Cowen and Company
New York
|
+$29.1M |
| 5 |
FAM
Fred Alger Management
New York
|
+$24.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$46M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$40.8M |
| 3 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$30.5M |
| 4 |
VC
Vivo Capital
Palo Alto,
California
|
-$22.7M |
| 5 |
PA
Perceptive Advisors
New York
|
-$16.4M |
CLDX Hedge Fund Activity: Q3 2021 in Review
160 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q3 2021, worth a combined $2.33B — up 95% from $1.19B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new CLDX positions and 14 closed out — a net gain of 30 holders — while 52 added to existing stakes and 46 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $246M. The largest seller was Eventide Asset Management, cutting an estimated $46M.
- 160 institutional investors held Celldex Therapeutics (CLDX) as of Q3 2021, up from 131 in Q2 2021.
- Funds reported $2.33B of Celldex Therapeutics stock for Q3 2021, up 95% quarter-over-quarter.
- 44 funds opened new Celldex Therapeutics positions in Q3 2021 and 14 closed out, a net change of +30 holders.
- The largest Celldex Therapeutics buyer in Q3 2021 was Fidelity Investments, an estimated $246M added.
- The largest Celldex Therapeutics seller in Q3 2021 was Eventide Asset Management, an estimated $46M sold.
Based on aggregated 13F filings for Q3 2021.